Exchange: NASDAQ·Updated 06:31 PM EST

GRI News

News
all
press releases
GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
The company said that the new data indicate that GRI-0621 may support the regeneration of lung tissue.
Stocktwits
GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lung disease with no known cause.read more...
Benzinga

Advertisement|Remove ads.